

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
10 October 2019 (10.10.2019)(10) International Publication Number
WO 2019/195720 A8(51) International Patent Classification:
A61K 9/50 (2006.01)

(21) International Application Number:

PCT/US2019/026054

(22) International Filing Date:

05 April 2019 (05.04.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/654,108

06 April 2018 (06.04.2018)

US

(71) Applicant: **BIOCRYST PHARMACEUTICALS, INC.**
[US/US]; 4505 Emperor Blvd., Suite 200, Durham, NC
27703 (US).


(72) Inventors: **KOTIAN, Pravin, L.**; 1139 Magnolia Run, Hoover, AL 35226 (US). **BABU, Yarlagadda S.**; 4836 Southlake Parkway, Birmingham, AL 35244 (US). **ZHANG, Weihe**; 2645 Manchester Court, Vestavia Hills, AL 35226 (US). **LU, Peng-Cheng**; 1816 Altadena Ridge Place, Vestavia Hills, Alabama 35243 (US). **WU, Minwan**; 2709 Paden Trail, Vestavia Hills, AL 35226 (US). **LV, Wei**; 5373 Park Side Circle, Hoover, AL 35244 (US). **NGUYEN, Trung, Xuan**; 5066 Park Side Circle, Hoover, AL 35244 (US). **DANG, Zhao**; 1226 Parliament Lane, Vestavia Hills, AL 35216 (US). **CHINTAREDDY, Venkat, R.**; 3134 Renfro Road, Vestavia Hills, AL 35216 (US). **KUMAR, V., Satish**; 809 Mayapple Court, Birmingham, AL 35244 (US). **RAMAN, Krishnan**; 3739 Spearman Drive, Birmingham, AL 35216 (US).

(74) Agent: **GORDON, Dana, M.** et al.; Foley Hoag LLP, Seaport West, 155 Seaport Boulevard, Boston, MA 02210-2600 (US).(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).**Declarations under Rule 4.17:**— *of inventorship (Rule 4.17(iv))***Published:**— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:

29 October 2020 (29.10.2020)

(54) Title: SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS



(57) Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

(15) Information about Correction:

see Notice of 29 October 2020 (29.10.2020)